<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00825734</url>
  </required_header>
  <id_info>
    <org_study_id>SCRI BRE 138</org_study_id>
    <nct_id>NCT00825734</nct_id>
  </id_info>
  <brief_title>Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer</brief_title>
  <official_title>Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer (MBC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SCRI Development Innovations, LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>SCRI Development Innovations, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, patients with metastatic HER2-negative breast cancer will receive treatment
      with ixabepilone and sorafenib until disease progression or unacceptable toxicity occurs. The
      Phase I portion of this study will determine the maximum tolerated doses (MTDs) of sorafenib
      and ixabepilone that may be used in combination for first- or second-line treatment of MBC.
      The MTDs identified in the Phase I portion of the study will be used in the Phase II portion
      which will evaluate the efficacy and safety of the combination of sorafenib and ixabepilone
      in patients who have received at least one prior chemotherapy treatment in either the
      adjuvant or neoadjuvant setting or following one prior MBC chemotherapy in MBC patients who
      had not received prior adjuvant or neoadjuvant breast cancer chemotherapy. This will be one
      of the initial trials investigating the use of this treatment combination for MBC.

      This trial will be conducted under the leadership of the Sarah Cannon Research Institute
      (SCRI) Oncology Research Consortium, a community-based, multi-center, clinical trial
      organization.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>every 9 weeks until treatment discontinuation or death on study</time_frame>
    <description>Measured from Day 1 of study drug administration to disease progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST) - progression is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>6-month Progression-Free Survival</measure>
    <time_frame>every 9 weeks, up to 6 months</time_frame>
    <description>Measured from Day 1 of study drug administration to disease progression as defined by RECIST v1.1, or death on study. Progression is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>every 9 weeks until discontinuation of treatment</time_frame>
    <description>Objective Response will be evaluated in this study using the Response Evaluation Criteria in Solid Tumors (RECIST).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>every 9 weeks until treatment discontinuation or death on study</time_frame>
    <description>Measured from Day 1 of study drug administration to date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Adverse Events as a Measure of of Safety and Tolerability</measure>
    <time_frame>every 9 weeks until treatment discontinuation or unacceptable toxicity</time_frame>
    <description>Assessments are made through analysis of reported incidence of treatment-emergent AEs and SAEs.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">83</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sorafenib PO BID (200mg), Ixabepilone IV every 21 days (40mg/m^2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level -1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sorafenib PO BID (200mg), Ixabepilone IV every 21 days (32mg/m^2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 1a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sorafenib PO BID (400mg), Ixabepilone IV every 21 days (32mg/m^2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>Dose Level 1 - Sorafenib PO BID (200mg) Dose Level -1 - Sorafenib PO BID (200mg) Dose Level 1a - Sorafenib PO BID (400mg)</description>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_label>Dose Level -1</arm_group_label>
    <arm_group_label>Dose Level 1a</arm_group_label>
    <other_name>Nexavar (Sorafenib)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ixabepilone</intervention_name>
    <description>Dose Level 1 - Ixabepilone IV every 21 days (40mg/m^2) Dose Level -1 - Ixabepilone IV every 21 days (32mg/m^2) Dose Level 1a - Ixabepilone IV every 21 days (32mg/m^2)</description>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_label>Dose Level -1</arm_group_label>
    <arm_group_label>Dose Level 1a</arm_group_label>
    <other_name>Ixempra (Ixabepilone)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years.

          2. Histologically or cytologically confirmed breast cancer diagnosis

        with metastatic disease. Patients without pathologic or cytologic

        confirmation of metastatic disease should have unequivocal

        evidence of metastasis.

        3. Measurable disease, as per RECIST criteria (Therasse et al.

        2000). Measurable disease cannot be previously irradiated

        unless progression was documented. Measurable disease is

        defined as: at least one lesion that can be accurately measured in

        at least one dimension [longest diameter to be recorded] as

        &gt;20 mm with conventional techniques, or as &gt;10 mm with spiral

        computed tomography (CT) scan. Disease must be measurable,

        i.e., bone-only disease or evaluable-only disease is not eligible.

        4. Patients with brain metastasis may participate if they:

        • have undergone appropriate treatment,

          -  are at least 1 month post-treatment,

          -  have no neurologic symptoms,

          -  are not on steroids,

          -  have a follow-up magnetic resonance imaging (MRI) scan that

        demonstrates no residual active lesions, and

          -  have no new untreated lesions.

             5 The following prior therapies are allowed:

          -  No prior chemotherapy in the metastatic setting. However,

        patients must have received prior adjuvant or neo-adjuvant

        chemotherapy.

          -  Prior radiation therapy in either the metastatic or early-stage

        setting, as long as &lt;25% of the bone marrow has been

        treated. Radiation therapy must be completed at least

        14 days prior to study registration, and all radiation-related

        toxicities must be resolved to ≤ grade 1 before the patient is

        eligible for study inclusion.

          -  Any number of hormonal therapies in the neo-adjuvant,

        adjuvant, or metastatic setting is allowed. Patients must

        discontinue hormonal therapy at least 1 week prior to starting

        study treatment.

        •Prior bevacizumab administered &gt;4 weeks before initiation of

        study treatment is allowed.

        6 HER2-negative status. Documentation of HER2 results must be

        available at the time of study enrollment. HER2-negative is

        defined as:

          -  Immunohistochemical (IHC) 0 or IHC 1+ OR

          -  Fluorescence in situ hybridization (FISH) negative (defined by

        FISH ratio &lt;2.2) OR

          -  Silver in-situ hybridization (SISH) negative (defined by SISH

        ratio &lt;2.2).

        Patients with an IHC 2+ will need to be validated as HER2-negative

        by FISH.

        7 An Eastern Cooperative Oncology Group (ECOG) performance

        status of &lt; or = to 2.

        8. Normal bone marrow function as defined by:

          -  absolute neutrophil count (ANC) &gt;1,500/μL;

          -  platelets &gt;100,000/μL;

          -  hemoglobin &gt;9 g/dL.

             9 Normal hepatic function as defined by:

          -  total bilirubin within normal institutional limits;

          -  aspartate aminotransferase (AST) and alanine

        aminotransferase (ALT) &lt;2.5 × the institutional upper limit of

        normal (ULN) for patients without liver metastasis; &lt;5.0 × ULN

        for patients with liver metastasis.

        10. Normal renal function as defined by creatinine &lt;1.5 × ULN.

        11. Left ventricular ejection fraction (LVEF) within institutional limits of

        normal.

        12. International normalized ratio (INR) &lt;1.5 or a prothrombin

        time/partial thromboplastin time (PT/PTT) within normal limits.

        Patients receiving anti-coagulation treatment with an agent such

        as warfarin or heparin may be allowed to participate. The INR

        should be measured prior to initiation of sorafenib, and for

        patients on warfarin, INR should be monitored at least weekly

        following initiation of protocol treatment, until the INR is stable and

        therapeutic.

        13. Life expectancy of &gt;6 months.

        14. For women of childbearing potential, negative serum pregnancy

        test within 7 days prior to starting treatment.

        15. For women of childbearing potential and men, agreement to use a

        method of contraception that is acceptable to their physician from

        time of first signing the informed consent and for the study

        duration. Men should use adequate birth control for at least three

        months after the last administration of sorafenib. If a woman

        becomes pregnant or suspects she is pregnant while participating

        in this study, she must agree to inform her treating physician

        immediately. As applicable, patients must agree to discontinue

        breast-feeding until at least 3 weeks after their last dose of study

        drug.

        16. Recovery to &lt; grade 1 toxicity due to prior therapy.

        17. Ability to understand and willingness to sign a written informed

        consent document.

        Exclusion Criteria

          1. More than one (&gt;1) prior chemotherapy regimen.

          2. Treatment with chemotherapy, biologic agents, or targeted agents

             within the previous 4 weeks.

          3. Previous treatment with sorafenib or ixabepilone.

          4. Women who are pregnant or breastfeeding.

          5. Neuropathy (motor or sensory) greater than grade 1.

          6. Uncontrolled intercurrent illness including (but not limited to)

             ongoing or active infection &gt;grade 2.

          7. Known history of human immunodeficiency virus (HIV), Hepatitis

             B, or Hepatitis C infection.

          8. History of other non-breast cancer malignancy treated with

             curative intent within the 5 years preceding study enrollment with

             the exception of carcinoma in situ of the cervix, non-melanoma

             skin cancer, or follicular thyroid cancer.

          9. Concurrent hormonal therapy, chemotherapy other than

             ixabepilone, or radiation treatments while on study as well as

             treatment with other investigational agents while on study.

         10. Cardiac disease:

             •Congestive heart failure (CHF) greater than New York Heart Association

             (NYHA) Class II (see Appendix B).

               -  Unstable angina (anginal symptoms at rest) or new onset angina

                  (i.e., began within the last 3 months).

               -  Myocardial infarction within the past 6 months.

               -  Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy.

         11. Uncontrolled hypertension (systolic blood pressure &gt;150 mmHg

             or diastolic pressure &gt;100 mmHg despite optimal medical

             management).

         12. Thrombolic or embolic events such as cerebrovascular accident,

             including transient ischemic attacks, within the past 6 months.

         13. Pulmonary hemorrhage or bleeding event ≥ grade 2 within

        4 weeks of the first dose of study treatment, or any other

        hemorrhage or bleeding event ≥ grade 3 within 4 weeks of the

        first dose of study treatment.

        14. Serious non-healing wound, ulcer, or bone fracture.

        15. Evidence or history of bleeding diathesis or coagulopathy.

        16. Major surgery, open biopsy or significant traumatic injury within

        4 weeks of the first dose of study drugs or anticipation of the need

        for major surgical procedure.

        17. Chronic use of CYP3A4 inducers and use of the following strong

        CYP3A4 inhibitors: ketoconazole, itraconazole, clarithromycin,

        atazanavir, nefazodone, saquinavir, telithromycin, ritonavir,

        amprenavir, indinavir, nelfinavir, delavirdine, and voriconazole.

        Use of these agents should be discontinued at least 72 hours

        prior to initiation of study treatment.

        18. Use of St. John's Wort or rifampin (rifampicin).

        19. Any condition that impairs patient's ability to swallow whole pills or

        gastrointestinal (GI) tract disease that involves an inability to take

        oral medication, malabsorption syndrome, a requirement for

        intravenous (IV) alimentation, prior surgical procedures affecting

        absorption, or uncontrolled inflammatory GI disease (e.g., Crohn's

        disease or ulcerative colitis).

        20. Psychiatric illness/social situations that would limit compliance

        with study requirements.

        21. Known or suspected allergy to sorafenib, Cremophor EL

        (polyoxyethylated castor oil) or a drug formulated in

        Cremophor EL such as paclitaxel or any other agent given in the

        course of this trial.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denise A. Yardley, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>SCRI Development Innovations, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Ft. Myers</city>
        <state>Florida</state>
        <zip>33916</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Medical Group</name>
      <address>
        <city>Terre Haute</city>
        <state>Indiana</state>
        <zip>47802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RHHP/ Hope Cancer Center</name>
      <address>
        <city>Terre Haute</city>
        <state>Indiana</state>
        <zip>47802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Hospital East</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Clinic, LLP</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Cancer and Blood Disorders</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Capital Clinical Research Consortium</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis Cancer Care</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Portsmouth Regional Hospital</name>
      <address>
        <city>Portsmouth</city>
        <state>New Hampshire</state>
        <zip>03801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology-Oncology Associates of Northern NJ</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Care</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Carolina Oncology Associates</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spartanburg Regional Medical Center</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2009</study_first_submitted>
  <study_first_submitted_qc>January 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2009</study_first_posted>
  <results_first_submitted>November 21, 2014</results_first_submitted>
  <results_first_submitted_qc>December 16, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 22, 2014</results_first_posted>
  <last_update_submitted>December 16, 2014</last_update_submitted>
  <last_update_submitted_qc>December 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic Breast Cancer</keyword>
  <keyword>Sorafenib</keyword>
  <keyword>Nexavar</keyword>
  <keyword>Ixabepilone</keyword>
  <keyword>Ixempra</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Epothilones</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited at multiple dose levels into the Dose Escalation (Phase I) portion of this study to determine the safest dose of this regimen (MTD-Maximum Tolerated Dose). Upon determination of this dose, patients being treated at the MTD proceeded to the Dose Expansion (Phase II) portion of the study and additional patients were recruited</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Dose Level 1</title>
          <description>Sorafenib PO BID (200mg), Ixabepilone IV every 21 days (40mg/m^2)</description>
        </group>
        <group group_id="P2">
          <title>Dose Level -1</title>
          <description>Sorafenib PO BID (200mg), Ixabepilone IV every 21 days (32mg/m^2)</description>
        </group>
        <group group_id="P3">
          <title>Dose Level 1a</title>
          <description>Sorafenib PO BID (400mg), Ixabepilone IV every 21 days (32mg/m^2)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Phase I</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">Patients were on-study until determination of the Maximum Tolerated Dose (MTD)</participants>
                <participants group_id="P2" count="0">Patients were on-study until determination of the Maximum Tolerated Dose (MTD)</participants>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Phase II</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="76">Includes patients treated at MTD during Phase I and 73 additional patients enrolled for Phase II</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="76"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Patients</title>
          <description>Patients treated at all dose levels in the Phase I and Phase II portions of the study
: Dose Level 1 (4 patients) Sorafenib PO BID (200mg), Ixabepilone IV every 21 days (40mg/m^2)
Dose Level -1 (3 patients) Sorafenib PO BID (200mg), Ixabepilone IV every 21 days (32mg/m^2)
Dose Level 1a (76 patients) Sorafenib PO BID (400mg), Ixabepilone IV every 21 days (32mg/m^2)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="83"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" lower_limit="30" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-Free Survival (PFS)</title>
        <description>Measured from Day 1 of study drug administration to disease progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST) - progression is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
        <time_frame>every 9 weeks until treatment discontinuation or death on study</time_frame>
        <population>Includes patients treated at the Phase II dose</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib and Ixabepilone</title>
            <description>Oral targeted therapy and Systemic Chemotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival (PFS)</title>
          <description>Measured from Day 1 of study drug administration to disease progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST) - progression is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
          <population>Includes patients treated at the Phase II dose</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" lower_limit="3.5" upper_limit="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>6-month Progression-Free Survival</title>
        <description>Measured from Day 1 of study drug administration to disease progression as defined by RECIST v1.1, or death on study. Progression is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
        <time_frame>every 9 weeks, up to 6 months</time_frame>
        <population>Includes patients treated at the Phase II dose</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib and Ixabepilone</title>
            <description>Oral targeted therapy and Systemic Chemotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>6-month Progression-Free Survival</title>
          <description>Measured from Day 1 of study drug administration to disease progression as defined by RECIST v1.1, or death on study. Progression is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
          <population>Includes patients treated at the Phase II dose</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate</title>
        <description>Objective Response will be evaluated in this study using the Response Evaluation Criteria in Solid Tumors (RECIST).</description>
        <time_frame>every 9 weeks until discontinuation of treatment</time_frame>
        <population>Includes patients treated at the Phase II dose who were evaluable for response</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib and Ixabepilone</title>
            <description>Oral targeted therapy and Systemic Chemotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate</title>
          <description>Objective Response will be evaluated in this study using the Response Evaluation Criteria in Solid Tumors (RECIST).</description>
          <population>Includes patients treated at the Phase II dose who were evaluable for response</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>Measured from Day 1 of study drug administration to date of death due to any cause.</description>
        <time_frame>every 9 weeks until treatment discontinuation or death on study</time_frame>
        <population>Includes patients treated at the Phase II dose</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib and Ixabepilone</title>
            <description>Oral targeted therapy and Systemic Chemotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>Measured from Day 1 of study drug administration to date of death due to any cause.</description>
          <population>Includes patients treated at the Phase II dose</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5" lower_limit="11" upper_limit="20.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Adverse Events as a Measure of of Safety and Tolerability</title>
        <description>Assessments are made through analysis of reported incidence of treatment-emergent AEs and SAEs.</description>
        <time_frame>every 9 weeks until treatment discontinuation or unacceptable toxicity</time_frame>
        <population>Patients treated at the Phase II dose</population>
        <group_list>
          <group group_id="O1">
            <title>Phase II - Sorafenib and Ixabepilone</title>
            <description>Oral targeted therapy and Systemic Chemotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Adverse Events as a Measure of of Safety and Tolerability</title>
          <description>Assessments are made through analysis of reported incidence of treatment-emergent AEs and SAEs.</description>
          <population>Patients treated at the Phase II dose</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Neutropenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Febrile neutropenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thrombocytopenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea/vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neuropathy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anorexia/weight loss</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia/myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alopecia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain in extremity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hand-foot syndrome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taste alteration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucositis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pruritus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Dose Level 1a</title>
          <description>Includes patients treated at the Phase II dose - Sorafenib PO BID (400mg), Ixabepilone IV every 21 days (32mg/m^2)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE v 4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>DEATH</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>INFECTION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>WEIGHT LOSS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE RENAL FAILURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>DYSPNEA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>PALMAR-PLANTAR ERYTHRODYSESTHESIA SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE v 4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANEMIA</sub_title>
                <counts group_id="E1" events="119" subjects_affected="27" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" events="114" subjects_affected="32" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" events="115" subjects_affected="36" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" events="65" subjects_affected="23" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>TACHYCARDIA</sub_title>
                <counts group_id="E1" events="19" subjects_affected="6" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="41" subjects_affected="10" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="56" subjects_affected="24" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>DIARRHEA</sub_title>
                <counts group_id="E1" events="126" subjects_affected="35" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>DRY MOUTH</sub_title>
                <counts group_id="E1" events="17" subjects_affected="4" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" events="35" subjects_affected="8" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>DYSPHAGIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>GASTROESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" events="17" subjects_affected="5" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>MUCOSITIS</sub_title>
                <counts group_id="E1" events="23" subjects_affected="13" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="141" subjects_affected="39" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="37" subjects_affected="20" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" events="26" subjects_affected="14" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>EDEMA</sub_title>
                <counts group_id="E1" events="36" subjects_affected="15" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="274" subjects_affected="61" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>FEVER</sub_title>
                <counts group_id="E1" events="19" subjects_affected="10" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="16" subjects_affected="7" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>ALLERGIC REACTION</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>INFECTION</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALKALINE PHOSPHATASE INCREASED</sub_title>
                <counts group_id="E1" events="16" subjects_affected="4" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>WEIGHT LOSS</sub_title>
                <counts group_id="E1" events="23" subjects_affected="11" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ANOREXIA</sub_title>
                <counts group_id="E1" events="76" subjects_affected="28" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>HYPERGLYCEMIA</sub_title>
                <counts group_id="E1" events="31" subjects_affected="8" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>HYPOKALEMIA</sub_title>
                <counts group_id="E1" events="21" subjects_affected="5" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="106" subjects_affected="29" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" events="99" subjects_affected="14" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="49" subjects_affected="13" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>BONE PAIN</sub_title>
                <counts group_id="E1" events="19" subjects_affected="8" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>FLANK PAIN</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" events="42" subjects_affected="15" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" events="88" subjects_affected="23" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="43" subjects_affected="12" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="29" subjects_affected="13" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>PERIPHERAL NEUROPATHY</sub_title>
                <counts group_id="E1" events="255" subjects_affected="41" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>TASTE ALTERATION</sub_title>
                <counts group_id="E1" events="50" subjects_affected="10" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" events="23" subjects_affected="6" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" events="31" subjects_affected="7" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" events="63" subjects_affected="11" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ALLERGIC RHINITIS</sub_title>
                <counts group_id="E1" events="26" subjects_affected="7" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="55" subjects_affected="19" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>DYSPNEA</sub_title>
                <counts group_id="E1" events="79" subjects_affected="23" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>NASAL CONGESTION</sub_title>
                <counts group_id="E1" events="12" subjects_affected="5" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>NASAL DRAINAGE</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" events="11" subjects_affected="5" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>SORE THROAT</sub_title>
                <counts group_id="E1" events="11" subjects_affected="6" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY INFECTION</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" events="174" subjects_affected="31" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>CALLUS</sub_title>
                <counts group_id="E1" events="41" subjects_affected="5" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>DESQUAMATION</sub_title>
                <counts group_id="E1" events="11" subjects_affected="6" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>DRY SKIN</sub_title>
                <counts group_id="E1" events="58" subjects_affected="9" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>ERYTHEMA</sub_title>
                <counts group_id="E1" events="11" subjects_affected="5" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>PALMAR-PLANTAR ERYTHRODYSESTHESIA SYNDROME</sub_title>
                <counts group_id="E1" events="46" subjects_affected="12" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" events="21" subjects_affected="10" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" events="158" subjects_affected="41" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>FLUSHING</sub_title>
                <counts group_id="E1" events="10" subjects_affected="4" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>HOT FLASHES</sub_title>
                <counts group_id="E1" events="18" subjects_affected="4" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="104" subjects_affected="26" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>LYMPHEDEMA</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John D. Hainsworth, MD</name_or_title>
      <organization>Sarah Cannon Research Institute</organization>
      <phone>1-877-691-7274</phone>
      <email>asksarah@scresearch.net</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

